BESIVANCE, A NEW TOPICAL FLUOROQUINILONE


Besivance is besifloxacin ophthalmic suspension, 0.6%. It prolongs the ocular survface residency time and therefore likely enhances therapeutic efficacy.

Comments

Popular posts from this blog

Keratoconus and Inflammatory Skin Conditions

CORNEA CROSS-LINKING RE-TREATMENT

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS